Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.  Helicore’s most advanced asset, HCR-188, is a clinical stage […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!